World’s First and Only Atrial Leadless Pacemaker
MAT-2403640 v2.0 | Item approved for U.S. use only. ©2025 Abbott. All Rights Reserved.
Atrial pacing replicates the heart's natural conduction system by stimulating the atrium, ensuring coordinated heart chamber contraction through the AV node and His-Purkinje system. The AVEIR AR Atrial Leadless Pacemaker, a first-of-its-kind technology from Abbott, offers a safe, effective, upgradeable solution for patients with sinus node dysfunction (SND) and normal AV intraventricular conduction systems. Key benefits include:
Presented by Dr. Devi Nair of St. Bernards Medical Center & Arrhythmia Research Group, this initial real-world experience data on the helix-fixation for the AVEIR AR LP demonstrated safe and effective implantation with 100% success, clinically viable electrical metrics, and no acute complications. This presentation introduces all the components while illustrating the dual helix design for atrial therapy.
ELECTRICAL PERFORMANCE SUCCESS RATE5 in early clinical evidence patients with acceptable atrial device capture threshold and sensing amplitude.*
FREEDOM FROM COMPLICATIONS.5 The inclusion of arrhythmias as a safety endpoint increased the overall incidence of complications compared with other studies of leadless pacemakers, which excluded arrhythmias from the endpoint.
*Atrial device capture threshold of ≤3.0V@04ms and ≥0.5mV at 3 month visit.
Real-world data demonstrated that the combination of AAI pacing and leadless pacemaker technology offers a safer, more efficient treatment of sick sinus syndrome (SSS) over transvenous pacing methods.
Explore the ongoing debate between AAI and DDD pacing for sick sinus syndrome (SSS). Learn how guidelines, trials, and innovations like leadless pacemakers, such as the AVEIR™ AR Atrial LP, influence clinical decisions to improve outcomes for SSS patients.
With its innovative features and promising early clinical evidence, AVEIR™ Atrial AR LP, only from Abbott, is poised to revolutionize leadless pacing by providing patients across the U.S. with access to advanced medical care.
Presentation at Heart Rhythm 2024 by Monica Lo, MD, FHRS, FACC
Patient therapy can be tailored by implanting an atrial device alone, or both atrial and ventricular devices together for dual chamber support. The option to upgrade over time allows you to meet your patient’s needs today and adapt to common disease progression later.
Treatment Option 1: Start with the Atrial Device.
Treat atrial arrhythmia and sinus node dysfunction today.
Add a ventricular device for heart block later.
i2i™ communication is enabled.
Activate dual chamber pacing therapy DDD(R) via i2i communication.
Treatment Option 2: Tailored Therapy with AAI(R)+VVI Pacing Mode.**
Start with a dual chamber device.
Turn off Beat-to-Beat communications to enable independent single chamber pacing for each device.
Treat SND patients today with an option of back-up ventricular pacing in the case of rare intermittent AV block.
**Note: AAI(R)+VVI mode should not be used in patients without intact AV node conduction or with chronic atrial fibrillation or atrial flutter.
REFERENCES
***For additional information about specific MR Conditional, including warnings, precautions, adverse conditions to MRI scanning and potential adverse events, please refer to the MRI-Ready Leadless Systems Manual at medical.abbott/manuals or check our MRI-Ready resources at cardiovascular.abbott/mriready
MAT-2501546 v1.0
Stay Connected